A new transmyocardial degradable stent combined with growth factor, heparin, and stem cells in acute myocardial infarction.
OBJECTIVE
We developed a new method-transmyocardial drilling revascularization (TMDR) with absorbable stent incorporated with basic fibroblast growth factor (bFGF) and heparin. The present study tested the effect of this method with transplantation of bone marrow-derived stem cells (BMSCs) in acute myocardial infarction.


RESULTS
Infarction was produced in mini-swine by ligating the left anterior descending (LAD) coronary artery. TMDR of 3.0 mm in diameter was made by mechanical drilling in the infarcted area. The animals that had LAD ligation were divided into six groups according to the procedures followed (n = 6 in each): control; T (TMDR); C (cell implantation); TS (TMDR+stent implantation); TC (TMDR+cell implantation); TSC (TMDR+stent implantation+cell implantation). Left ventricular (LV) function, myocardial perfusion, vascular density, and histological and morphological analyses were evaluated pre-operatively and at 30 min and 6 weeks post-operatively. Six weeks after operation, the above indices were significantly better in the TSC group than in other groups (P < 0.001 compared with the control group, and P < 0.05 or 0.01 compared with the TS and TC groups), although TS and TC also showed better results than the control group (P < 0.05).


CONCLUSIONS
We have demonstrated in a pig model that an intramyocardial stent implanted with slow release of bFGF, heparin, and BMSC transplantation may significantly increase LV function, cardiac blood flow, and vascular density. Therefore, the present study may provide a new method for the surgical treatment of myocardial infarction.
Wang
Ying
Y
Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Liu
Xiao-Cheng
XC
Zhang
Guang-Wei
GW
Zhao
Jian
J
Zhang
Jie-Min
JM
Shi
Rong-Fang
RF
Huang
Yun-Zhou
YZ
Zhao
Chun-Hua
CH
Liu
Tian-Jun
TJ
Song
Cun-Xian
CX
Lü
Feng
F
Yang
Qin
Q
He
Guo-Wei
GW
D020341:Absorbable Implants; D000818:Animals; D003331:Coronary Vessels / Q000502:physiology; D004195:Disease Models, Animal; D054855:Drug-Eluting Stents; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage / Q000627:therapeutic use*; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D045164:Mesenchymal Stem Cell Transplantation; D009203:Myocardial Infarction / Q000503:physiopathology / Q000628:therapy*; D018919:Neovascularization, Physiologic / Q000502:physiology; D012039:Regional Blood Flow / Q000502:physiology; D013552:Swine; D013556:Swine, Miniature; D018487:Ventricular Dysfunction, Left / Q000503:physiopathology / Q000628:therapy
D005343:Fibrinolytic Agents; D016222:Fibroblast Growth Factor 2; D006493:Heparin